OOIR: Observatory of International Research

Papers

(The TQCC of Oncoimmunology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells	86
Ferroptosis: friend or foe in cancer immunotherapy?	83
ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer	73
The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers?	53
Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity	52
Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration	51
HIF2A mediates lineage transition to aggressive phenotype of cancer-associated fibroblasts in lung cancer brain metastasis	48
Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients	48
A targeted MAVS fusion protein for controlled innate immune activation and antitumor therapy	46
Nanoparticles releasing immunogenic cell death inducers upon near-infrared light exposure	45
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2	45
Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer	43
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	40
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment	39
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors	39
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype	35
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment	34
DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway	34
Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis	34
The ART of tumor immune escape	33
Antibody–drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties	32
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity	32
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials	32
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer	30
Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response	30

Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer	28
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint in	28
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7 ^th immunorad conference	27
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)	27
L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes	26
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors	26
Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues	26
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy	26
PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma	26
Cellular senescence enhances adaptive anticancer immunosurveillance	26
Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses	25
The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma	25
Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance	25
MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4 ⁺ T cells in vivo	25
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities	24
A mitochondrial checkpoint to adaptive anticancer immunity	24
Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying a bispecific T cell engager against hepatocellular carcinoma	24
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection	24
HUNK as a key regulator of tumor-associated macrophages in triple negative breast cancer	24
Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer	24
Group 2 innate lymphoid cells boost CD8 ⁺ T-cell activation in anti-tumor immune responses	24
RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome	23
FGL2 _172-220 peptides improve the antitumor effect of HCMV-IE1mut vaccine against glioblastoma by modulating immunosuppressive cells in the tumor microenvironment	23
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy	23
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade	23
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma	23
CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies	23
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies	22
Clusterin protects mature dendritic cells from reactive oxygen species mediated cell death	22
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutan	22
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)	21
Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells	21
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)	21
A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin	21
MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells	20
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	20
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	20
Whole stromal fibroblast signature is linked to specific chemokine and immune infiltration patterns and to improved survival in NSCLC	19
Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1	19
Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors	19
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status	19
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer	19
Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice	19
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition	18
CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors	18
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma	18
Immunoreactivity against fibroblast growth factor 8 in alveolar rhabdomyosarcoma patients and its involvement in tumor aggressiveness	17
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors	17
IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response	17
PDIA3 as a potential bridge between immunogenic cell death and autoreactivity	17

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1	17
Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes	17
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody	17
Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils	17
Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system	16
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer	16
Functional and molecular characterization of PD1 ⁺ tumor-infiltrating lymphocytes from lung cancer patients	16
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting	16
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis	16
Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates	16
MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma	16
Deep learning using bulk RNA-seq data expands cell landscape identification in tumor microenvironment	16
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence	16
A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer	16
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer	15
STING is significantly increased in high-grade glioma with high risk of recurrence	15
Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer	15
ADA/CD26 axis increases intra-tumor PD-1 ⁺ CD28 ⁺ CD8 ⁺ T-cell fitness and affects NSCLC progno	15
Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer	15
Human NK cells and cancer	15
PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells	15
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure	15
An oncogene regulating chromatin favors response to immunotherapy	14
FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population	14
Cell type-specific induction of ferroptosis to boost antitumor immunity	14
Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance	14
Trial watch: anticancer vaccination with dendritic cells	14
The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response	14
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade	14
The potential role of CMC1 as an immunometabolic checkpoint in T cell immunity	14
High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils	13
Memory-like differentiation enhances NK cell responses against colorectal cancer	13
Metabolic heterogeneity in tumor cells impacts immunology in lung squamous cell carcinoma	13
CD39 ⁺ conventional CD4 ⁺ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade	13
Tumor-infiltrating lymphocytes for melanoma immunotherapy	12
Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment	12
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 ⁺ T cells eradicates peritoneal metastases in mouse models	12
An integral membrane constitutively active heparanase enhances the tumor infiltration capability of NK cells	12
Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy	12
Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy	12
IL-15 transpresentation by ovarian cancer cells improves CD34 ⁺ progenitor-derived NK cell's anti-tumor functionality	11
Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression	11
Association between immune-related adverse event timing and treatment outcomes	11
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA	11
Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles	11
TNBC-derived Gal3BP/Gal3 complex induces immunosuppression through CD45 receptor	11
Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas	11
Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors	11
CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage	11
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression	11
The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma	11
Hyperdifferentiated murine melanoma cells promote adaptive anti-tumor immunity but activate the immune checkpoint system	11
Enriched circulating and tumor-resident TGF-β ⁺ regulatory B cells in patients with melanoma promote FOXP3 ⁺ Tregs	11
Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome	11
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer	11